Respiratory Syncytial Virus (RSV) Infections – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Respiratory Syncytial Virus (RSV) Infections – Pipeline Review, H2 2016’, provides an overview of the Respiratory Syncytial Virus (RSV) Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Respiratory Syncytial Virus (RSV) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Respiratory Syncytial Virus (RSV) Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Respiratory Syncytial Virus (RSV) Infections

The report reviews pipeline therapeutics for Respiratory Syncytial Virus (RSV) Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Respiratory Syncytial Virus (RSV) Infections therapeutics and enlists all their major and minor projects

The report assesses Respiratory Syncytial Virus (RSV) Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Respiratory Syncytial Virus (RSV) Infections

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Respiratory Syncytial Virus (RSV) Infections

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Respiratory Syncytial Virus (RSV) Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Abivax SA

Ablynx NV

ADMA Biologics, Inc.

Agilvax, Inc.

Aridis Pharmaceuticals LLC

Artificial Cell Technologies, Inc.

AstraZeneca Plc

Aviragen Therapeutics, Inc.

Bavarian Nordic A/S

Celltrion, Inc.

Codagenix, Inc.

Curevac AG

DBV Technologies S.A.

Emergent BioSolutions Inc.

Enanta Pharmaceuticals, Inc.

Evec, Inc.

F. Hoffmann-La Roche Ltd.

Gene Techno Science Co., Ltd.

GenVec, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline Plc

Globavir Biosciences, Inc.

Humabs BioMed SA

iBio, Inc.

ILiAD Biotechnologies, LLC

Ilyang Pharmaceutical Co., Ltd

Immunovaccine Inc

Inovio Pharmaceuticals, Inc.

Johnson & Johnson

Karyopharm Therapeutics, Inc.

Kineta, Inc.

mAbxience S.A.

MedImmune LLC

Medivir AB

Merck & Co., Inc.

Mucosis B.V.

Mymetics Corporation

NanoBio Corporation

Navigen Pharmaceuticals, Inc.

NeuClone Pty Ltd

Novavax, Inc.

Panacea Biotec Limited

Profectus BioSciences, Inc.

Pulmocide Ltd

Regeneron Pharmaceuticals Inc

Romark Laboratories, L.C.

Spider Biotech

Spring Bank Pharmaceuticals, Inc.

Takeda Pharmaceutical Company Limited

TechnoVax, Inc.

The International Biotechnology Center (IBC) Generium

Themis Bioscience GmbH

Trellis Bioscience, Inc.

Vault Pharma Inc.

Vaxart Inc

VaxInnate Corporation

VBI Vaccines Inc

Virometix AG

Visterra, Inc.

VLP Biotech, Inc.

Table of Contents

Table of Contents

Table of Contents 2

Introduction 6

Respiratory Syncytial Virus (RSV) Infections Overview 7

Therapeutics Development 8

Respiratory Syncytial Virus (RSV) Infections - Therapeutics under Development by Companies 10

Respiratory Syncytial Virus (RSV) Infections - Therapeutics under Investigation by Universities/Institutes 14

Respiratory Syncytial Virus (RSV) Infections - Pipeline Products Glance 15

Respiratory Syncytial Virus (RSV) Infections - Products under Development by Companies 18

Respiratory Syncytial Virus (RSV) Infections - Products under Investigation by Universities/Institutes 23

Respiratory Syncytial Virus (RSV) Infections - Companies Involved in Therapeutics Development 25

Respiratory Syncytial Virus (RSV) Infections - Therapeutics Assessment 85

Drug Profiles 95

Respiratory Syncytial Virus (RSV) Infections - Dormant Projects 237

Respiratory Syncytial Virus (RSV) Infections - Discontinued Products 242

Respiratory Syncytial Virus (RSV) Infections - Product Development Milestones 243

Appendix 254

List of Tables

List of Tables

Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections, H2 2016 20

Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections – Comparative Analysis, H2 2016 21

Number of Products under Development by Companies, H2 2016 22

Number of Products under Development by Companies, H2 2016 (Contd..1) 23

Number of Products under Development by Companies, H2 2016 (Contd..2) 24

Number of Products under Development by Companies, H2 2016 (Contd..3) 25

Number of Products under Investigation by Universities/Institutes, H2 2016 26

Comparative Analysis by Late Stage Development, H2 2016 27

Comparative Analysis by Clinical Stage Development, H2 2016 28

Comparative Analysis by Early Stage Development, H2 2016 29

Products under Development by Companies, H2 2016 30

Products under Development by Companies, H2 2016 (Contd..1) 31

Products under Development by Companies, H2 2016 (Contd..2) 32

Products under Development by Companies, H2 2016 (Contd..3) 33

Products under Development by Companies, H2 2016 (Contd..4) 34

Products under Investigation by Universities/Institutes, H2 2016 35

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 36

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Abivax SA, H2 2016 37

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Ablynx NV, H2 2016 38

Respiratory Syncytial Virus (RSV) Infections – Pipeline by ADMA Biologics, Inc., H2 2016 39

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Agilvax, Inc., H2 2016 40

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Aridis Pharmaceuticals LLC, H2 2016 41

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Artificial Cell Technologies, Inc., H2 2016 42

Respiratory Syncytial Virus (RSV) Infections – Pipeline by AstraZeneca Plc, H2 2016 43

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Aviragen Therapeutics, Inc., H2 2016 44

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Bavarian Nordic A/S, H2 2016 45

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Celltrion, Inc., H2 2016 46

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Codagenix, Inc., H2 2016 47

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Curevac AG, H2 2016 48

Respiratory Syncytial Virus (RSV) Infections – Pipeline by DBV Technologies S.A., H2 2016 49

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Emergent BioSolutions Inc., H2 2016 50

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Enanta Pharmaceuticals, Inc., H2 2016 51

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Evec, Inc., H2 2016 52

Respiratory Syncytial Virus (RSV) Infections – Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 53

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Gene Techno Science Co., Ltd., H2 2016 54

Respiratory Syncytial Virus (RSV) Infections – Pipeline by GenVec, Inc., H2 2016 55

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Gilead Sciences, Inc., H2 2016 56

Respiratory Syncytial Virus (RSV) Infections – Pipeline by GlaxoSmithKline Plc, H2 2016 57

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Globavir Biosciences, Inc., H2 2016 58

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Humabs BioMed SA, H2 2016 59

Respiratory Syncytial Virus (RSV) Infections – Pipeline by iBio, Inc., H2 2016 60

Respiratory Syncytial Virus (RSV) Infections – Pipeline by ILiAD Biotechnologies, LLC, H2 2016 61

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Ilyang Pharmaceutical Co., Ltd, H2 2016 62

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Immunovaccine Inc, H2 2016 63

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Inovio Pharmaceuticals, Inc., H2 2016 64

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Johnson & Johnson, H2 2016 65

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Karyopharm Therapeutics, Inc., H2 2016 66

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Kineta, Inc., H2 2016 67

Respiratory Syncytial Virus (RSV) Infections – Pipeline by mAbxience S.A., H2 2016 68

Respiratory Syncytial Virus (RSV) Infections – Pipeline by MedImmune LLC, H2 2016 69

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Medivir AB, H2 2016 70

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Merck & Co., Inc., H2 2016 71

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Mucosis B.V., H2 2016 72

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Mymetics Corporation, H2 2016 73

Respiratory Syncytial Virus (RSV) Infections – Pipeline by NanoBio Corporation, H2 2016 74

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Navigen Pharmaceuticals, Inc., H2 2016 75

Respiratory Syncytial Virus (RSV) Infections – Pipeline by NeuClone Pty Ltd, H2 2016 76

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Novavax, Inc., H2 2016 77

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Panacea Biotec Limited, H2 2016 78

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Profectus BioSciences, Inc., H2 2016 79

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Pulmocide Ltd, H2 2016 80

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 81

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Romark Laboratories, L.C., H2 2016 82

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Spider Biotech, H2 2016 83

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Spring Bank Pharmaceuticals, Inc., H2 2016 84

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 85

Respiratory Syncytial Virus (RSV) Infections – Pipeline by TechnoVax, Inc., H2 2016 86

Respiratory Syncytial Virus (RSV) Infections – Pipeline by The International Biotechnology Center (IBC) Generium, H2 2016 87

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Themis Bioscience GmbH, H2 2016 88

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Trellis Bioscience, Inc., H2 2016 89

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Vault Pharma Inc., H2 2016 90

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Vaxart Inc, H2 2016 91

Respiratory Syncytial Virus (RSV) Infections – Pipeline by VaxInnate Corporation, H2 2016 92

Respiratory Syncytial Virus (RSV) Infections – Pipeline by VBI Vaccines Inc, H2 2016 93

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Virometix AG, H2 2016 94

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Visterra, Inc., H2 2016 95

Respiratory Syncytial Virus (RSV) Infections – Pipeline by VLP Biotech, Inc., H2 2016 96

Assessment by Monotherapy Products, H2 2016 97

Assessment by Combination Products, H2 2016 98

Number of Products by Stage and Target, H2 2016 100

Number of Products by Stage and Mechanism of Action, H2 2016 102

Number of Products by Stage and Route of Administration, H2 2016 104

Number of Products by Stage and Molecule Type, H2 2016 106

Respiratory Syncytial Virus (RSV) Infections – Dormant Projects, H2 2016 249

Respiratory Syncytial Virus (RSV) Infections – Dormant Projects (Contd..1), H2 2016 250

Respiratory Syncytial Virus (RSV) Infections – Dormant Projects (Contd..2), H2 2016 251

Respiratory Syncytial Virus (RSV) Infections – Dormant Projects (Contd..3), H2 2016 252

Respiratory Syncytial Virus (RSV) Infections – Dormant Projects (Contd..4), H2 2016 253

Respiratory Syncytial Virus (RSV) Infections – Discontinued Products, H2 2016 254

List of Figures

List of Figures

Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections, H2 2016 20

Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections – Comparative Analysis, H2 2016 21

Number of Products under Development by Companies, H2 2016 22

Number of Products under Investigation by Universities/Institutes, H2 2016 26

Comparative Analysis by Clinical Stage Development, H2 2016 28

Comparative Analysis by Early Stage Products, H2 2016 29

Assessment by Monotherapy Products, H2 2016 97

Number of Products by Top 10 Targets, H2 2016 99

Number of Products by Stage and Top 10 Targets, H2 2016 99

Number of Products by Mechanism of Actions, H2 2016 101

Number of Products by Stage and Mechanism of Actions, H2 2016 101

Number of Products by Routes of Administration, H2 2016 103

Number of Products by Stage and Routes of Administration, H2 2016 103

Number of Products by Top 10 Molecule Types, H2 2016 105

Number of Products by Stage and Top 10 Molecule Types, H2 2016 105

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports